PharmaEssentia Corporation (TWSE: 6446) announced that results from its Phase 3 SURPASS-ET clinical trial have been published in The Lancet ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE